Spring til hovedindhold

Sundhedsaktier

Har du givet din portefølje et helbredstjek?

Med en sektor, der i de fleste udviklede lande fylder mere end 10% af landets BNP, udgør sundhedsindustrien en stor del af det globale aktiemarked.

I USA er hver 8. person ansat inden for sundhed (healthcare), og branchen fylder tæt på 18 procent af USA's BNP.

Ved investering i sundhedssektoren har du mulighed for at investere i virksomheder, der fremmer den globale sundhed og udvikler medicin og produkter, der kan forlænge levetiden.

De fleste danske investorer kender Novo Nordisk - den danske gigant inden for diabetes, blødningsbehandling og behandling af overvægt.

Sundhed er altså en sektor, der fylder meget i aktiemarkedet, og hvor du har mulighed for gode afkast.

Mere om sundhedsaktier på vores blog

Værdipapirerne i oversigterne er ikke ment som investeringsanbefalinger, men en generel oversigt over de muligheder, der findes. Finansielle instrumenter kan både stige og falde i værdi. Der er en risiko for, at du ikke får de investerede penge tilbage, og vi gør opmærksom på, at historiske afkast ikke er garanti for fremtidige afkast. Inden du investerer i en fond, bør du læse prospektet, som er tilgængeligt hos fondsselskabet og central investorinformation, som du finder i ordreafgivelsesvinduet samt på fondens produktside på nordnet.dk.

Nordiske Aktier.

AstraZeneca
Børsværdi
2.102.600 MSEK
Ejere?
17.867
3m
+6,07%
AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and marketing of prescription drugs, primarily for the treatment of diseases in the areas of therapy that affect the respiratory tract, cardiovascular / metabolism, and cancer. In addition to its main operations, the company is also active in autoimmunity, neuroscience, and infection. AstraZeneca is active in all global regions and is headquartered in Cambridge.
Lundbeck
Børsværdi
25.252 MDKK
Ejere?
16.788
3m
-9,02%
Lundbeck er en farmaceutisk virksomhed. Det største fokus findes i forskning om psykiatriske og neurotiske lidelser, som omfatter behandling af depression, skizofreni, Alzheimers og Parkinsons syndrom. Virksomheden driver forskning, udvikling og videre distribution af lægemidler, hvor kunder findes på globalt plan. Virksomheden blev grundlagt i 1915 og har sit hovedkontor med beliggenhed i Valby.
Novo Nordisk
Børsværdi
2.161.212 MDKK
Ejere?
80.038
3m
+14,98%
Novo Nordisk er producent af insulin til behandling af diabetes. Ud over specialkundskaben inden for diabetes producerer virksomheden lægemidler til hormonbehandling, samt produkter til hæmofili og blødningsforstyrrelser. Produkterne findes på det globale marked og sælges under separate mærker. Virksomheden blev oprindeligt grundlagt i 1923 og har hovedsæde i Bagsværd.
Orion
Børsværdi
6.947 MEUR
Ejere?
15.371
3m
+6,51%
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo.
Pfizer
Børsværdi
2.536.101 MSEK
Ejere?
3.186
3m
-12,07%
Pfizer is a pharmaceutical company. The company conducts research and development, as well as the production of pharmaceuticals. The greatest focus is found in immunology, cardiovascular and metabolic diseases, as well as oncology and treatment of rare diseases. The business is managed via most business segments, where the company operates in a global market, mainly in North America and Europe. Pfizer was originally founded in 1849 and is headquartered in New York.

Globale aktier.

Abbott Laboratories
Børsværdi
191.706 MUSD
Ejere?
1.747
3m
+10,37%
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
AbbVie
Børsværdi
258.693 MUSD
Ejere?
3.156
3m
-1,33%
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Bayer AG
Børsværdi
55.900 MEUR
Ejere?
2.732
3m
+6,72%
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins. The firm has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.
Bristol-meyers Squibb co
Børsværdi
154.040 MUSD
Ejere?
831
3m
-6,25%
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Eli lilly & Company
Børsværdi
325.056 MUSD
Ejere?
1.286
3m
-5,42%
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Gilead sciences inc
Børsværdi
105.018 MUSD
Ejere?
1.648
3m
+5,15%
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Johnson & Johnson
Børsværdi
439.835 MUSD
Ejere?
5.746
3m
-7,36%
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
Novartis AG
Børsværdi
193.012 MUSD
Ejere?
989
3m
+11%
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Sanofi
Børsværdi
122.180 MUSD
Ejere?
314
3m
+12,82%
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Teva Pharmaceutical Industries
Børsværdi
11.392 MUSD
Ejere?
8.246
3m
+15,15%
Based in Israel, Teva is one of the world’s largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company’s branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva’s portfolio rationalization has resulted in less overall price erosion versus peers.
UnitedHealth Group
Børsværdi
454.140 MUSD
Ejere?
636
3m
-11,88%
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

ETF'er.

Her kan du se et udvalg af de ETF'er, der findes inden for sundhedssektoren. Hvis du ønsker at se alle mulighederne, kan du benytte dig af vores ETF-screener.

iShares S&P 500 Health Care Sector
Årlige omkostninger
0,15%
Aktivklasse
Aktie
Risiko
The investment objective of the Fund is to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the S&P 500 Capped 35/20 Health Care Index. In order to achieve this investment objective, the investment policy of the Fund is to invest in a portfolio of equity securities that as far as possible and practicable consist of the component securities of the S&P 500 Capped 35/20 Health Care Index, this Fund’s Benchmark Index. The Fund intends to replicate the constituents of the Benchmark Index by holding all the securities comprising the Benchmark Index in a similar proportion to their weightings in the Benchmark Index. In order to replicate its Benchmark Index, this Fund may invest up to 20% of its Net Asset Value in shares issued by the same body. This limit may be raised to 35% for a single issuer when exceptional market conditions apply (as set out in section 4 of Schedule III).
iShares MSCI World Health Care Sector
Årlige omkostninger
0,25%
Aktivklasse
Aktie
Risiko
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the MSCI World Health Care ESG Reduced Carbon Select 20 35 Capped Index.
iShares STOXX Europe 600 Health Care
Årlige omkostninger
0,46%
Aktivklasse
Aktie
Risiko
The investment seeks to replicate, net of expenses, the STOXX Europe 600 Health Care TR index as closely as possible. The fund invests in physical index securities. The index offers exposure to the European Health care sector as defined by the Industry Classification Benchmark (ICB). It is a sub index of the Europe STOXX 600 index.

Nordnet­ Markets.

Få eksponering mod aktier, råvarer og indeks i både op- og nedgang.

Se udvalget her

Alle investeringer i finansielle instrumenter er forbundet med risiko og kan både stige og falde i værdi. Læs mere om risiko.